99067-96-6

Basic information

• Product Name: Benzenamine, 4-(isocyanatomethyl)-N,N-dimethyl-
• CAS NO: 99067-96-6
• Molecular Formula: C10H12N2O
• Molecular Weight: 176.218
• Mol File: 99067-96-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzenamine, 4-(isocyanatomethyl)-N,N-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 4-(isocyanatomethyl)-N,N-dimethyl-(99067-96-6)
• EPA Substance Registry System: Benzenamine, 4-(isocyanatomethyl)-N,N-dimethyl-(99067-96-6)

Safety Data

• Hazardous Substances Data: 99067-96-6(Hazardous Substances Data)

Upstream product

• 10003-74-4 4-(dimethylamino)benzylamine dihydrochloride salt 
• 503-38-8 trichloromethyl chloroformate 
• 1197-19-9 4-cyano-N,N-dimethylaniline 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 19293-58-4 (4-aminomethylphenyl)dimethylamine 
• 6767-29-9 4-dimethylaminobenzeneacetic acid methyl ester 
• 100133-14-0 (4-dimethylamino-phenyl)-acetic acid hydrazide 
• 17078-28-3 2-[4-(dimethylamino)phenyl]acetic acid 

Downstream Products

• 1326247-13-5 C₂₅H₄₃N₅O₂ 
• 1326247-12-4 C₂₅H₄₃N₅O₂ 
• 1202780-56-0 C₂₅H₄₅N₅O₂ 
• 1202780-58-2 C₂₃H₄₁N₅O₂ 
• 1228766-53-7 3-(2-ethylhexyl)-3'-(4-(dimethylamino)benzyl)-1,3-bisureidopropane 

Relevant articles and documents

Design, synthesis and anticancer activity of a new series of n-aryl-n′-[4-(Pyridin-2-ylmethoxy)benzyl]urea derivatives

The development of cancer treatments requires continuous exploration and improvement, in which the discovery of new drugs for the treatment of cancer is still an important pathway. In this study, based on the molecular hybridization strategy, a new structural framework with an N-aryl-N’-arylmethylurea scaffold was designed, and 16 new target compounds were synthesized and evaluated for their antiproliferative activities against four different cancer cell lines A549, MCF7, HCT116, PC3, and human liver normal cell line HL7702. The results have shown seven compounds with 1-methylpiperidin-4-yl groups having excellent activities against all four cancer cell lines, and they exhibited scarcely any activities against HL7702. Among them, compound 9b and 9d showed greatly excellent activity against the four kinds of cells, and the IC50 for MCF7 and PC3 cell lines were even less than 3μM.

Structure-based drug design and potent anti-cancer activity of tricyclic 5:7:5-fused diimidazo[4,5-d:4′,5′-f][1,3]diazepines

Judicial structural modifications of 5:7-fused ring-expanded nucleosides (RENs), based on molecular modeling studies with one of its known targets, human RNA helicase (hDDX3), led to the lead, novel, 5:7-5-fused tricyclic heterocycle (1). The latter exhibited promising broad-spectrum in vitro anti-cancer activity against a number of cancer cell lines screened. This paper describes our systematic, albeit limited, structure-activity relationship (SAR) studies on this lead compound, which produced a number of analogs with broad-spectrum in vitro anti-cancer activities against lung, breast, prostate, and ovarian cancer cell lines, in particular compounds 15i, 15j, 15m and 15n which showed IC 50 values in submicromolar to micromolar range, and are worthy of further explorations. The SAR data also enabled us to propose a tentative SAR model for future SAR efforts for ultimate realization of optimally active and minimally toxic anti-cancer compounds based on the diimidazo[4,5-d:4′, 5′-f][1,3]diazepine structural skeleton of the lead compound 1.

TRPV1 vanilloid receptor antagonists with a bicyclic portion

The invention discloses compounds of formula I wherein Y s selected from a group of formula and W, Q, n, R1, R2, R3, U1-U5 have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1. 1.